Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 4/20 | 0.45 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | NAMPT | P43490 | 4/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | CSF1R | P07333 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | BRAF | P15056 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1989364 | 0.90 | KMT2A (0.42) | MEN1LMNAKMT2AMAPK1SMN1; SMN2 | |
| SCHEMBL1993594 | 0.89 | NAMPT (0.44) | LMNAKMT2ASMN1; SMN2NAMPTNPC1 | |
| SCHEMBL1988741 | 0.88 | CYP3A4 (0.43) | LMNAMAPTMAPK1SMN1; SMN2 | |
| SCHEMBL1991847 | 0.87 | SMN1; SMN2 (0.40) | MEN1LMNAKMT2AMAPTSMN1; SMN2 | |
| SCHEMBL1992887 | 0.84 | CYP3A4 (0.40) | MEN1KMT2ASMN1; SMN2NAMPTRAB9A | |
| SCHEMBL974202 | 0.84 | WDR5 (0.41) | LMNA | |
| SCHEMBL1989763 | 0.83 | CYP3A4 (0.38) | MEN1KMT2A | |
| SCHEMBL977153 | 0.83 | SLC6A9 (0.38) | — | |
| SCHEMBL977155 | 0.83 | SLC6A9 (0.38) | — | |
| SCHEMBL1990367 | 0.83 | TP53 (0.36) | KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110152236-A1 | AZETIDINE POLYSUBSTITUTED COMPOUNDS, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2011-06-23 | — | — | US | claimed |
| US-20110152236-A1 | AZETIDINE POLYSUBSTITUTED COMPOUNDS, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152236-A1 | AZETIDINE POLYSUBSTITUTED COMPOUNDS, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF | C1R, TACR1, C1S | CYP11B2 387/4885CYP11B1 605/4885MEN1 1088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.